Regulus Therapeutics Inc. – Consensus Indicates Potential -23.1% Downside

Broker Ratings

Regulus Therapeutics Inc. found using ticker (RGLS) have now 3 analysts covering the stock with the consensus suggesting a rating of ‘Hold’. The target price ranges between 1.5 and 0.5 calculating the mean target price we have 1. Given that the stocks previous close was at 1.3 this would indicate that there is a downside of -23.1%. There is a 50 day moving average of 0.77 while the 200 day moving average is 0.69. The market cap for the company is $90m. Find out more information at:

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its two lead product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase Ib clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products, which include RGLS5579 to inhibit miR-10b, and Hepatitis B virus program and Non-Alcoholic Steatohepatitis program. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index